Report Code: A01037 | Nov 2023 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Asia Pacific Hormone Refractory Breast Cancer Market
Request Now !Breast cancer is the most common type of malignant cancer prevalent in women above the age of 40. According to the estimates of World Health Organization, cancer is the most fatal human disease accounting for the deaths of ~8.2 million people worldwide in 2012. Among these deaths, breast cancer was found to be most prominent disease among women that killed ~521,000 individuals. Presently, increasing number of hormone therapies have made refractory breast cancers resistant toward therapeutics, termed as hormone-resistant breast cancers. However, recently developed hormone refractory breast cancer chemotherapeutic agents such as, trastuzumab and everolimus, alone or in combination, are under clinical trials for the effective treatment of hormone refractory breast cancers.
Key factors responsible for the growth of this market involve increasing incidences of breast cancers, aging population, demands of advanced therapeutics, increasing prevalence of hormone refractory breast cancers, and the presence of a significant number of anticancer pipeline drugs. Rising life span of cancer-affected population is one of the other factors responsible for the growth of this market. However, social stigma of testing breast cancer lacks technological reach. Insufficient advanced chemotherapeutic treatments restraining the hormone refractory breast cancer market. Substantial number of new chemical entities (NCEs) in various phases of clinical trials will emerge as potential opportunities in the Asia Pacific market.
The Asia Pacific hormone refractory breast cancer market is segmented into China, Japan, India, Australia and others. The Asia-Pacific region is expected to rise at the significant pace, owing to rapid growth of pharmaceutical and healthcare industry along with the improved purchasing power of the service providers in this region. Rapidly emerging economies and the rise of medical tourism in regions such as India and China, will drive the growth of hormone refractory breast cancer market. Rising kidney failure, prevalence rates, in the Asia-Pacific regions should boost the growth of this market.
KEY BENEFITS
Asia Pacific Hormone Refractory Breast Cancer Market Report Highlights
Aspects | Details |
---|---|
By TREATMENT |
|
By Application |
|
By Region |
|
Key Market Players | NeoCorp GmbH, Boehringer Ingelheim GmbH, AstraZeneca, Bluefish Pharmaceuticals AB, AmpliMed Corporation, F. Hoffmann La Roche, Fresenius Kabi, Sanofi Genzyme, Neopharm, Anant Pharmaceuticals Pvt. Ltd. |
Start reading.
This Report and over 66,782+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers